Lamivudine-13C, d2

Lamivudine-13C, d2 is the deuterium labeled and 13C-labeled Lamivudine. Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI) . Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS[1][2].

2714473-70-6

12352005

HBV

Anti-infection

COVID-19-anti-virus

Cancer; Infection

NC1=N[13C](N([C@@H]2CS[C@H](C(O)([2H])[2H])O2)C=C1)=O

C7 13CH9D2N3O3S

232.26

[1]Colledge D, et al. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 1997 Jul;26 (1) :216-25. |[2]Olaniyan LW, et al. Lamivudine-Induced Liver Injury. Open Access Maced J Med Sci. 2015 Dec 15;3 (4) :545-50.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W654247/

Reference compound1

No Development Reported